Strength:
- Docetaxel Kabi 20 mg/1 ml
- Docetaxel Kabi 80 mg/4 ml
- Docetaxel Kabi 120 mg/6 ml
For all indications, toxicities may warrant dosage adjustments. Administer in a facility equipped to manage possible complications (e.g. anaphylaxis).
Breast Cancer
• For locally advanced or metastatic breast cancer after failure of prior chemotherapy, the recommended dose of Docetaxel is 60 mg/m2 to 100 mg/m2 administered intravenously over 1 hour every 3 weeks.
• For the adjuvant treatment of operable node-positive breast cancer, the recommended Docetaxel dose is 75 mg/m2 administered 1 hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks for 6 courses. Prophylactic G-CSF may be used to mitigate the risk of hematological toxicities
Non-Small Cell Lung Cancer
• For treatment after failure of prior platinum-based chemotherapy, Docetaxel was evaluated as monotherapy, and the recommended dose is 75 mg/m2 administered intravenously over 1 hour every 3 weeks. A dose of 100 mg/m2 in patients previously treated with chemotherapy was associated with increased hematologic toxicity, infection, and treatment-related mortality in randomized, controlled trials.
• For chemotherapy-naïve patients, Docetaxel was evaluated in combination with cisplatin. The recommended dose of Docetaxel is 75 mg/m2 administered intravenously over 1 hour immediately followed by cisplatin 75 mg/m2 over 30-60 minutes every 3 weeks.
Prostate cancer
• For hormone-refractory metastatic prostate cancer, the recommended dose of Docetaxel is 75 mg/m2 every 3 weeks as a 1 hour infusion. Prednisone 5 mg orally twice daily is administered continuously.
Gastric adenocarcinoma
• For gastric adenocarcinoma, the recommended dose of Docetaxel is 75 mg/m2 as a 1 hour intravenous infusion, followed by cisplatin 75 mg/m2, as a 1 to 3 hour intravenous infusion (both on day 1 only), followed by fluorouracil 750 mg/m2 per day given as a 24-hour continuous intravenous infusion for 5 days, starting at the end of the cisplatin infusion. Treatment is repeated every three weeks. Patients must receive premedication with antiemetics and appropriate hydration for cisplatin administration.
Head and Neck Cancer
• Patients must receive premedication with antiemetics, and appropriate hydration (prior to and after cisplatin administration). Prophylaxis for neutropenic infections should be administered. All patients treated on the Docetaxel containing arms of the TAX323 and TAX324 studies received prophylactic antibiotics.
